Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort.

[1]  H. S. Kim,et al.  The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients. , 2019, Urologic oncology.

[2]  Jaegil Kim,et al.  The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. , 2019, European urology.

[3]  S. Daneshmand,et al.  Validation of the cobra nomogram for the prediction of cancer specific survival in patients with bladder cancer treated with radical cystectomy , 2019, European Urology Supplements.

[4]  Mauro A. A. Castro,et al.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer , 2019, European urology.

[5]  M. Cooperberg,et al.  The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy , 2017, Cancer.

[6]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[7]  K. Hoadley,et al.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.

[8]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[9]  R. Millikan,et al.  A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. , 2016, European urology.

[10]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[11]  M. Ghoneim,et al.  Prediction of survival after radical cystectomy for invasive bladder carcinoma: risk group stratification, nomograms or artificial neural networks? , 2009, The Journal of urology.

[12]  Yair Lotan,et al.  Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.

[13]  M. Terris,et al.  Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: Results from multiple cohorts including TCGA. , 2019, The Journal of urology.

[14]  P. Karakiewicz,et al.  External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. , 2012, European urology.